

### First Health Services Corporation

# Re-gaining Control of Pharmaceutical Costs While Preserving Clinical Outcomes

Kenneth Kolb, Pharm.D.

TennCare Bureau







- Introductions
- TennCare Objectives
- Corporate Experience & Capabilities Overview
- First Health Services' Solution
- Implementation and Operations Plan
- Expected Results & Pricing
- Q&A, Discussion







- Cut minimum \$150M in annualized Rx costs from FY04 TennCare budget
- Preserve clinical integrity of TennCare
- Gain TennCare provider participation in program success
- Transition seamlessly from current program to future operations
- Position TennCare for continued cost containment










#### Fiscal Agent Services

- Pharmacy Benefit Administration Services
- Healthcare Management Services

#### First Health Group Corp Revenue









Note: Year indicates initial contract date for each state.





# First Health is a PBA, not PBM

# Pharmacy Benefits Administrator

- Transparent Business Model
- Admin Fees Only
- Work solely in interest of State/patient
- No Pharma \$ = No conflicts





# First Health Services Drug Management Programs

- Point-of-Sale Claims Processing
- Prospective & Concurrent DUR
- Prior Authorization of Medication Therapy
- Retrospective DUR
- Prescriber Education Programs
- Rebate Contracting & Administration
- Pharmacy Reimbursement Methodologies
- Preferred Drug Management System
- National Medicaid Pooling Initiative





Initiative	Estimated Minimum Savings	Estimated Maximum Savings
POS with Custom ProDUR <sup>1</sup>	5%	10%
PDL with Supplemental Rebates <sup>2</sup>	8%	17%
Clinical Review Services (Managed Access Process) <sup>3</sup>	3%	5%
Drug Rebate Management (OBRA '90) 4	1%	3%
Maximum Allowable Cost (MAC) Implementation <sup>5</sup>	3%	5%

<sup>1</sup> Savings based on use of FHSC custom criteria and actual savings achieved in FHSC client States


- 2 Savings will vary based upon level of manufacturer participation, PDL compliance and State decision-making about program design
- 3 Savings vary based upon aggressiveness of clinical protocols
- 4 Savings vary based upon State's current level of effectiveness in CMS rebate administration typical collection rate exc drug spend
- $\,\,$  Savings vary based upon current pharmacy reimbursement levels





# Drug Spend Management Services

#### **Savings Potential of Various Programs**




**Months After Initial Implementation** 



# Florida vs. Michigan Relative Cost-Savings Performance

#### Trends:

- National Average = 19.8%
- Florida = 15.1% \*
- Michigan = 2.3%



\* Florida results include effect of 4-brand limit initiative





#### **PDL Models**



- Finds best net price among therapeutically equivalent brands, generics
- Therapeutic equivalence determined by state-based P&T
   Committee
- Shifts market share
- Rebate-driven Model (FL)
  - Maximizing discounts from existing brand use
  - Does not necessarily lower drug trend
- Voluntary Model (OR, MS)
  - 50% PDL compliance







- Several cost saving opportunities
  - PPI's
  - Non-sedating antihistamines
- On the Horizon
  - SSRI's fluoxitene, now paroxitene
  - Lipid-lowering agents
  - Anti-migraine drugs
- Remember in a value-based market most major categories can churn





# P&T or DUR Board deliberation – example PPI's


- Clinical question- Do any of the PPI's warrant special consideration based on unique action or side effect profile? – NO
- Therefore is the P&T Committee willing to endorse a decision based on price – YES
- Do we have a pharmaceutical company willing to provide deep discounting to become a virtual exclusive provider of PPI's to the state? - YES
- The P&T Committees for all First Health clients to date have endorsed this approach and subsequently have saved their states literally millions of dollars.





# PDL Shifts Prescribing Patterns

**12 Month Overall Compliance Level = 95.68%** 








# Clinical Review, then Cost

- Therapeutic class analysis and annotated review
  - Clinical decisions first
- National P&T
  - Applies first tier analysis of issues
- State-based P&T
  - Final arbiter of PDL product selections
  - Consider net lowest cost among therapeutically equivalent products






# Relationship Between Amount Paid/Claim & Utilization of Single-Source Brands








**Complex Interrelationships** 






## **Pharmacy Cost Drivers**

















#### Generics to OTC

- More benefit design than cost savings
- Manufacturers gambling that the public will pay for the brand
- Non-issue in Medicaid
- State will require an Rx and MAC the generic version
- Disease Management in Medicaid
  - Experiments ongoing
  - OPPAGA report in FL said state left \$64.2 M in real dollars on the table by accepting value-added programs
  - FH approach is through coordination of care





- Mental Health Drugs
  - Highly charged issue
  - Advocacy/Pharma influence
  - Valid questions on relative effectiveness need to be addressed for the safety of patients
  - First Health is leveraging its expertise in MH care management to help clients find solutions
- Specialty Pharmacy
  - In-office injectables
  - Not a focus until now
  - High cost/high utilization area
  - Next wave of focused UR







## **Challenges**

### PhRMA's Blocking legislation

- NY PDL: \$400M in savings, on hold until authorizing legislation passed
- Attempts to limit scope:
  - carving out drug classes,
  - limiting use of prior authorization
  - Grand-fathering current patients/drugs

### Canadian re-importation

Difficult Policy Decision





### Wrap-up

- Medicaid is in long term financial trouble even with the transfer of some dual eligibles to the Medicare drug benefit
- First Health has a major and growing presence in the Medicaid market with a proven tool set
- First Health is an innovator and is bringing advanced systems and solutions to the market

